Form 4: Terns Pharmaceuticals Director Reports Option Cancellation

Director Jeffrey B. Kindler reports the cancellation of stock options following the acquisition of Terns Pharmaceuticals by Merck.

Summary

• Director Jeffrey B. Kindler filed a Form 4 reporting the cancellation of various stock options.
• The cancellation occurred on May 5, 2026, as a result of the merger between Terns Pharmaceuticals and Merck Sharp & Dohme LLC.
• A total of 208,505 options with varying exercise prices ranging from $1.82 to $34.60 were cancelled.
• Under the merger agreement, these options were converted into the right to receive the cash difference between the $53.00 merger consideration and the respective exercise prices.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the merger provides a definitive exit at a set cash price, reflecting the successful realization of value for the company's assets.

Positives

• The merger consideration of $53.00 per share represents a significant liquidity event for shareholders and option holders.
• The transaction successfully closed, providing certainty for stakeholders.

Negatives

• The company will cease to exist as an independent publicly traded entity following the merger completion.

Risks

• The company is no longer an independent entity, and all future operational risks are now integrated into the acquirer, Merck.

Future Outlook

The company has been acquired by Merck; therefore, no independent future guidance or outlook is provided.

Industry Context

StockSavvy.ai notes that this acquisition follows a broader trend of large pharmaceutical companies like Merck aggressively acquiring mid-cap biotech firms to bolster their clinical pipelines, particularly in specialized therapeutic areas.

Comparison to Industry Standards

• The $53.00 per share cash offer is consistent with recent premium-based acquisitions in the biotechnology sector.
• The conversion of unvested options into cash consideration is a standard practice in change-of-control transactions.

Stakeholder Impact

• Shareholders receive $53.00 per share in cash.
• Option holders receive cash payouts based on the spread between the merger price and their exercise price.

Next Steps

• Finalization of payments to option holders.
• Delisting of Terns Pharmaceuticals from public exchanges.

Key Dates

Keywords

Terns Pharmaceuticals, Merck, Merger, Acquisition, Form 4, Stock Options, Biotech